Published in Nat Rev Cancer on July 01, 2004
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med (2011) 3.84
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A (2008) 3.30
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res (2008) 3.05
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol (2008) 2.63
Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab (2014) 2.48
Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol (2010) 2.46
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol (2008) 2.04
Recent progress in tumor pH targeting nanotechnology. J Control Release (2008) 1.94
Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res (2008) 1.91
Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer (2012) 1.87
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
IQGAP1 and its binding proteins control diverse biological functions. Cell Signal (2011) 1.77
The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res (2005) 1.76
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA (2008) 1.73
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70
Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res (2010) 1.69
DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab (2012) 1.67
Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol (2005) 1.65
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 1.63
Mouse models of breast cancer metastasis. Breast Cancer Res (2006) 1.62
Targeting insulin-like growth factor pathways. Br J Cancer (2006) 1.57
Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol (2012) 1.57
Metformin for aging and cancer prevention. Aging (Albany NY) (2010) 1.51
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2009) 1.50
Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A (2009) 1.45
Genome-environment interactions that modulate aging: powerful targets for drug discovery. Pharmacol Rev (2011) 1.42
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 1.40
Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 1.39
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 1.31
Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer (2005) 1.31
IGF-1R as an anti-cancer target--trials and tribulations. Chin J Cancer (2013) 1.31
Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS One (2008) 1.30
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30
The role of IGF-1R in pediatric malignancies. Oncologist (2009) 1.27
Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr (2011) 1.26
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res (2008) 1.24
Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. Mol Cancer (2007) 1.24
Oncogene homologue Sch9 promotes age-dependent mutations by a superoxide and Rev1/Polzeta-dependent mechanism. J Cell Biol (2009) 1.23
Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol (2011) 1.22
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res (2005) 1.22
Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY) (2010) 1.22
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica (2009) 1.21
Combinatorial RNAi for quantitative protein network analysis. Proc Natl Acad Sci U S A (2007) 1.21
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res (2010) 1.20
Evolutionary determinants of cancer. Cancer Discov (2015) 1.19
Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci (2007) 1.19
A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet (2010) 1.18
Can genes for mammographic density inform cancer aetiology? Nat Rev Cancer (2008) 1.17
Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.17
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer (2006) 1.16
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res (2006) 1.16
ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro. Mol Cancer (2010) 1.15
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res (2009) 1.15
The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol (2010) 1.13
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A (2006) 1.11
Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res (2009) 1.10
Growth hormone regulation of insulin-like growth factor-I gene expression may be mediated by multiple distal signal transducer and activator of transcription 5 binding sites. Endocrinology (2008) 1.09
Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis (2011) 1.09
Epidermal insulin/IGF-1 signalling control interfollicular morphogenesis and proliferative potential through Rac activation. EMBO J (2008) 1.09
Cixutumumab. Expert Opin Investig Drugs (2009) 1.09
Molecular mechanisms of mouse skin tumor promotion. Cancers (Basel) (2010) 1.09
Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol (2010) 1.08
Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control (2011) 1.07
Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol (2007) 1.05
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res (2009) 1.04
Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat (2011) 1.04
Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book (2013) 1.04
Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. Int J Cancer (2011) 1.03
Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia (2012) 1.03
Circulating tumor cells, enumeration and beyond. Cancers (Basel) (2010) 1.03
Perinatal and family risk factors for non-Hodgkin lymphoma in early life: a Swedish national cohort study. J Natl Cancer Inst (2012) 1.03
Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol (2013) 1.02
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res (2010) 1.02
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. Invest New Drugs (2011) 1.02
Starvation, detoxification, and multidrug resistance in cancer therapy. Drug Resist Updat (2012) 1.01
Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults. Growth Horm IGF Res (2008) 1.01
Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res (2013) 1.01
Colorectal cancer survivorship: movement matters. Cancer Prev Res (Phila) (2011) 1.01
Fetal growth and childhood cancer: a population-based study. Pediatrics (2013) 1.01
Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis (2015) 1.01
IGF-1 promotes the development and cytotoxic activity of human NK cells. Nat Commun (2013) 1.00
Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol (2013) 1.00
Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther (2011) 1.00
A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer (2011) 1.00
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate (2008) 1.00
Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer (2007) 1.00
Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci U S A (2011) 0.99
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat (2013) 0.99
MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS One (2014) 0.99
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer (2005) 8.19
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
A prospective study of sleep duration and mortality risk in women. Sleep (2004) 6.11
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet (2008) 4.57
Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst (2004) 4.57
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Aspirin intake and survival after breast cancer. J Clin Oncol (2010) 4.50
Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA (2011) 4.25
Rotating night shift work and risk of type 2 diabetes: two prospective cohort studies in women. PLoS Med (2011) 3.88
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst (2006) 3.65
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst (2004) 3.28
Adult weight change and risk of postmenopausal breast cancer. JAMA (2006) 3.11
Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol (2006) 3.09
Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet (2009) 3.06
The role of prolactin in mammary carcinoma. Endocr Rev (2003) 2.95
Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies. Ann Intern Med (2010) 2.95
Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst (2003) 2.92
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol (2007) 2.80
Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev (2004) 2.75
Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology (2007) 2.73
Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol (2004) 2.72
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med (2005) 2.66
Melatonin secretion and the incidence of type 2 diabetes. JAMA (2013) 2.65
Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum (2004) 2.62
Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am J Clin Nutr (2007) 2.56
Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation (2003) 2.52
A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol (2007) 2.50
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.37
Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer (2005) 2.35
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Night work and risk of breast cancer. Epidemiology (2006) 2.30
Night shift work and the risk of endometrial cancer. Cancer Res (2007) 2.28
Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res (2006) 2.27
A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 2.23
Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension (2002) 2.16
Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst (2002) 2.16
Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn (2010) 2.15
A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev (2005) 2.15
Physical activity and risk of breast cancer among postmenopausal women. Arch Intern Med (2010) 2.15
Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol (2006) 2.14
Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev (2006) 2.14
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet (2012) 2.12
Challenges to the measurement of estradiol: an endocrine society position statement. J Clin Endocrinol Metab (2013) 2.11
Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res (2011) 2.11
Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev (2004) 2.10
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst (2011) 2.09
Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 2.09
Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat (2013) 2.07
Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab (2007) 2.07
Teenage acne and cancer risk in US women: A prospective cohort study. Cancer (2015) 2.05
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A (2011) 2.03
Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care (2003) 2.02
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2007) 2.01
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer (2007) 2.01
Age at menarche and risk of type 2 diabetes: results from 2 large prospective cohort studies. Am J Epidemiol (2009) 1.99
Cigarette smoking and the incidence of breast cancer. Arch Intern Med (2011) 1.97
Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol (2010) 1.95
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev (2007) 1.95
Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst (2013) 1.94
Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev (2002) 1.91
Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med (2004) 1.91
Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol (2010) 1.90
Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr (2004) 1.88
Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med (2010) 1.88
Work characteristics and incidence of type 2 diabetes in women. Am J Epidemiol (2006) 1.88
The association of self-reported sleep duration, difficulty sleeping, and snoring with cognitive function in older women. Alzheimer Dis Assoc Disord (2006) 1.85
Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol (2012) 1.85
Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst (2005) 1.84
Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res (2010) 1.82
Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res (2007) 1.82
A prospective study of dietary fat consumption and endometriosis risk. Hum Reprod (2010) 1.79
Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol (2008) 1.79
Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation (2004) 1.78
Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev (2008) 1.77
Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet (2011) 1.77
Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control (2010) 1.77
A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer (2007) 1.76
Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med (2006) 1.74